Luliconazole is a topical antifungal agent used to treat fungal infections. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu.
- Mechanism
- Curator reviewed
The exact mechanism of action for luliconazole's anti-fungal activity is still not known, but luliconazole is thought to inhibit the enzyme lanosterol demethylase. Lanosterol demethylase is needed for the synthesis of ergosterol, which is a major component of the fungus cell membranes.
- Primary indication
- Luliconazole is indicated for the treatment of interdigital tinea pedis, tinea cruris, or tinea corporis infections caused by Trichophyton rubrum and Epidermophyton floccosum.Curator reviewed · 2 structured indications
- Formula / weight
- C14H9Cl2N3S2 · 354.27 g/mol (avg)
- First approval
- United States, 2013
- Code names
- NND-502 · PR-2699
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
YTAOBBFIOAEMLL-REQDGWNSSA-NSMILESClC1=CC(Cl)=C(C=C1)[C@@H]1CS\C(S1)=C(\C#N)N1C=CN=C1Targets
What you can answer from here — as of June 15, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Luliconazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account